Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Iedereen een gezond en mooi jaar gewenst.
Hier sluit ik me bij aan, en dan nog eens een succesvol 2022 voor ons Sopheon aandeelhouders er bij.
marblesthegame schreef op 31 december 2021 09:11 :
Iedereen een gezond en mooi jaar gewenst.
Jij en iedereen hier op het forum een gezond en mooi jaar gewenst en dat 2022 ons Sopheon mag worden. Groet ABC
Ook van mij een gezond en geweldig Soof-jaar toegewenst!
Is het ooit zo stil geweest? Geen beweging in te krijgen, toch dood geld!!
Lijkt wel of Soof voor anker gegaan is. Ze mogen nu wel weer eens naar de Noord varen. Gr Arie de Beuker
Wat een verkoop vandaag? Hangt er weer negativiteit in de lucht!
Sopheon PLC Issue of Equity RNS Number : 7129Y Sopheon PLC 17 January 2022 For immediate release SOPHEON PLC ("Sopheon" or the "Company") Issue of Equity - Option Exercise Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, announces that, following the exercise of options by certain employees, it has allotted 41,109 new Ordinary Shares of 20 pence each in the Company ("Ordinary Shares"). Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 21 January 2022. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 10,553,325. The Company does not hold any shares in treasury. Accordingly, the figure of 10,553,325 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Zag het te laat, dit was al aangekondigd.
En door deze enorme verwatering hebben we de 9 verlaten!!!!!!!!!! (lol)
Vorig jaar de 25ste de trading update, ben benieuwd of we woensdag wat meer horen, het is uiterst stil!!!
www.linkedin.com/posts/robbybollen_te... Een andere medewerker had ook op Linkedinn iets gepost met op de achtergrond een raket omhoog op haar laptop. Inmiddels is die foto vervangen... Gr Arie de Beuker
Aan de koers te zien gaat hij stijl naar beneden;-)))
Trading Update Sopheon, the international provider of software and services for Enterprise Innovation Management solutions, is pleased to provide the following trading update for the year ended 31 December 2021. On 20 December 2021 we reported our acquisition of the ROI Blueprints (“ROIB”) business, along with a statement that financial performance would be comfortably in line with market expectations. We are now delighted to report that we expect that revenue for the year ended 31 December 2021 will exceed $34m (2020: $30m). Annual Recurring Revenue (“ARR”) at the end of 2021 is expected to exceed $20.5m (2020: $18m), a performance we are pleased with. This, coupled with contracted consulting services, means that revenue visibility1 for 2022 has grown to approximately $23.4m (2020: $22.0m). Adjusted EBITDA is expected to exceed $6m (2020: $5.9m). Net cash on 31 December 2021 was $24.1m (2020: $21.6m) after funding the initial payment on the ROI Blueprints acquisition, demonstrating the cash generative nature and resilient cash performance of the business and underlining our robust balance sheet. In addition to the revenue out-performance, the profit result was assisted by the deferral of some of our anticipated investment plans, in particular in the staffing of product development. Like many other software businesses, we face ongoing challenges in recruiting technical staff. However, as noted in previous announcements, along with the appointment of Greg Coticchia as CEO in April, we have added new leadership in sales, marketing and product areas and expanded resources in 2021. We have increased the pace of Accolade product releases, and also expanded a number of marketing initiatives to build the Sopheon profile, and grow the pipeline. This includes programs to introduce the ROIB solution to our customer base later this month. Several cross-sell opportunities have been identified, and the ROIB team is already fully integrated at Sopheon. Our growth initiatives will continue and accelerate in 2022. The improvement in ARR underlines continued traction in our migration to a Software as a Service (“SaaS”) recurring revenue model, giving both enhanced revenue visibility to future periods and improved quality of earnings. Approximately 50% of more than 70 license transactions signed during 2021 were for SaaS contracts. Moreover, the value of SaaS bookings was more than double that of perpetual contracts. This includes another six existing customers converting from the perpetual model to a SaaS model. Gross retention of ARR returned to our normal strong levels, at 95% compared to 91.5% during the challenging conditions of 2020. Financial expectations noted above are preliminary, and subject to year-end financial close and audit review processes. In line with our normal reporting schedule, Sopheon plans to issue its results for the year ended 31 December 2021 on 24 March 2022.Sopheon’s Chairman, Andy Michuda said: “As I noted in our December announcement, it was great to end the year with our first acquisition for some time, coupled with strong execution in the core business. We continue to explore and evaluate further M&A opportunities. In parallel, we are also advancing nicely on our stated transition towards a SaaS business, both operationally as well as financially, intended to enhance predictability, quality of earnings and overall shareholder return. I am encouraged with the foundational progress Greg and the team have made in 2021 and look forward to further positive developments as the new year progresses.” For further information contact: Andy Michuda (Chairman) Arif Karimjee (CFO) Sopheon plc + 44 (0) 1276 919 560www.sopheon.com/financial-releases/tr... Bertus S.
Geen verrassingen vind ik, Gr Arie de Beuker
In ieder geval geen lijken uit de kast, maar ook geen raket die ons door die vreselijk barrière van 10 pond heen gaat drukken. Weer een jaar van achter over leunen en hopen op ooit die uitschieter!
Arie de Beuker schreef op 25 januari 2022 08:27 :
Geen verrassingen vind ik,
Gr
Arie de Beuker
Omzet +14% ARR +13,9% Net cash +11% SAAS = saai maar ook leuk. Groet ABC.
Prima resultaten hoor wat mij betreft. Erg tevreden met de nieuwe wegen die Greg Coticchia en Michuda hebben ingezet. De 10 pond en verder is een kwestie van tijd. Zou onder de vlag van Mence allemaal nog veel langer hebben geduurd.
vlg Finncap SOPHEON (SPE): CORP Positive end to 2021 leads to promising start for 2022 too After the positive December trading update accompanying the acquisition of ROI Blueprints, today’s update gives detail of 2021 outperformance in both revenue & EBITDA, with net cash at year end of $24.1m vs $21.9m, even after the acquisition. Revenue of over $34m (>+3% vs $33mE) delivered 14% growth vs FY20, and returned EBITDA over $6.0m, +35% vs. expectations and +2% vs FY20, at a margin of 18% instead of 14%E. In addition to revenue outperformance, deployment of planned increased costs was deferred by the well-known challenges to IT recruitment experienced across the industry, with positive consequences for profitability and cash (+10% vs $21.9mE) – nevertheless, the group continues to invest in sales, marketing, product & expanded resources, an increased pace of Accolade releases, and expanded market initiatives to build the pipeline. Importantly, the group’s KPIs in ARR and retention continued to demonstrate improving earnings quality, with ARR +14% at $20.5m (vs $18.0m in FY20 and $19.0m at 1H21), and 95% gross retention (vs 91.5% FY20). Combined with contracted consulting revenue due for recognition within the year, the group has once again set a record for full-year visibility by this stage of the year at a total of $23.4m (vs $22.0m at FY21). We leave forecasts unchanged, while nudging up our target price to 1250p (1200p), leaving plenty of capacity for outperformance as the world opens up during the year.
- Sopheon has delivered FY21 forecasts ahead of expectations, echoing routine pre-COVID. Our target price remains based on 4.1x FY22 EV/Sales, and we expect organic growth to be complemented by M&A through use of the $24.1m cash, while maintaining a strong cash balance to reassure enterprise clients. - The focus for growth remains on KPIs, with the growing importance of ARR, as the percentage of SaaS revenue expands within the recognised revenue. Of more than 70 licence transactions signed in 2021 (FY20: 35, 1H21: 43 as the COVID backlog cleared), more than 50% were SaaS contracts, while the total value of SaaS contracts signed was double that of perpetual. Six existing customers (FY20: 4) converted to SaaS, heavily skewed to 1H21 (5), while retention of the remaining licence/maintenance customers returned to 95% (FY20: 91.5%) post the initial experience of lockdowns. Visibility of 2022 revenue incorporates ARR and also additional contracted revenue (such as consultancy) for recognition in FY22. Visibility currently stands at $23.4m (FY20: $22m), representing 63% of FY22 revenue expectations, comparing with 63-65% experienced in FY19-FY21. Outperformance has returned, having been a recurring theme for pre COVID Sopheon during 2016-2019, given the level of operational gearing in the model. The deferral of some planned spend in product development staff has added to EBITDA outperformance in the current year, but the group continues to treat M&A as a viable alternative to R&D, and to invest in sales, marketing, product, and additional resources.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,79
+0,96%
EUR/USD
1,0703
+0,48%
FTSE 100
8.044,81
+0,26%
Germany40^
18.161,70
+1,68%
Gold spot
2.322,02
-0,22%
NY-Nasdaq Composite
15.696,64
+1,59%
Stijgers
Dalers